Cargando…

Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients

Objective. To evaluate safety and immune responses of personalized peptide vaccination (PPV) for hepatitis C virus- (HCV-) positive advanced hepatocellular carcinoma (HCC). Patients and Methods. Patients diagnosed with HCV-positive advanced HCC were eligible for this study. A maximum of four HLA-mat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yutani, Shigeru, Ueshima, Kazuomi, Abe, Kazumichi, Ishiguro, Atsushi, Eguchi, Junichi, Matsueda, Satoko, Komatsu, Nobukazu, Shichijo, Shigeki, Yamada, Akira, Itoh, Kyogo, Sasada, Tetsuro, Kudo, Masatoshi, Noguchi, Masanori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619935/ https://www.ncbi.nlm.nih.gov/pubmed/26539554 http://dx.doi.org/10.1155/2015/473909

Ejemplares similares

Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients' Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine
por: Yutani, Shigeru, et al.
Publicado: (2013)

Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies
por: Yutani, Shigeru, et al.
Publicado: (2017)

Identification of B cell epitopes reactive to human papillomavirus type-16L1- derived peptides
por: Fukui, Akimasa, et al.
Publicado: (2012)

Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients
por: Suekane, Shigetaka, et al.
Publicado: (2020)

A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer
por: Shirahama, Takahisa, et al.
Publicado: (2017)

Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele
por: Sakamoto, Shinjiro, et al.
Publicado: (2015)

Antitumor activity of antibody against cytotoxic T lymphocyte epitope peptide of lymphocyte‐specific protein tyrosine kinase
por: Matsueda, Satoko, et al.
Publicado: (2018)

Immunological evaluation of peptide vaccination for cancer patients with the HLA ‐A11(+) or ‐A33(+) allele
por: Sakamoto, Shinjiro, et al.
Publicado: (2017)

Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma
por: Suekane, Shigetaka, et al.
Publicado: (2017)

Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers
por: Noguchi, Masanori, et al.
Publicado: (2018)

Humoral Immune Responses to EGFR-Derived Peptides Predict Progression-Free and Overall Survival of Non-Small Cell Lung Cancer Patients Receiving Gefitinib
por: Azuma, Koichi, et al.
Publicado: (2014)

Investigation of factors associated with reduced clinical benefits of personalized peptide vaccination for pancreatic cancer
por: Uchino, Yoshihiro, et al.
Publicado: (2021)

Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients
por: Iwasa, Satoru, et al.
Publicado: (2016)

Identification of novel Lck‐derived T helper epitope long peptides applicable for HLA‐A2(+) cancer patients as cancer vaccine
por: Matsueda, Satoko, et al.
Publicado: (2015)

Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination
por: Sakamoto, Shinjiro, et al.
Publicado: (2015)

Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients
por: Takahashi, Ryuji, et al.
Publicado: (2013)

A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
por: Noguchi, Masanori, et al.
Publicado: (2013)

Personalized peptide vaccination for advanced colorectal cancer
por: Sasada, Tetsuro, et al.
Publicado: (2015)

Association of haptoglobin genetic polymorphism with overall survival in advanced castration-resistant prostate cancer patients with personalized peptide vaccination
por: Komatsu, Nobukazu, et al.
Publicado: (2013)

Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer
por: Muroya, Daisuke, et al.
Publicado: (2016)

Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial
por: Noguchi, Masanori, et al.
Publicado: (2020)

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer
por: Sasada, Tetsuro, et al.
Publicado: (2013)

Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients
por: Takahashi, Ryuji, et al.
Publicado: (2014)

Plasma level of prostate related-antigen peptide-reactive IgG is a prognostic factor of patients with breast cancer treated with personalized peptide vaccines
por: Saku, Shuko, et al.
Publicado: (2021)

Elevation of Serum MAGE‐4 Protein Levels and Prediction of Hepatocellular Carcinogenesis in Patients with Liver Cirrhosis
por: Yutani, Shigeru, et al.
Publicado: (2002)

Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy
por: Kawano, Kouichiro, et al.
Publicado: (2015)

Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2(+) cancer patients
por: Shomura, H, et al.
Publicado: (2004)

A Gene Encoding Antigenic Peptides of Human Squamous Cell Carcinoma Recognized by Cytotoxic T Lymphocytes
por: Shichijo, Shigeki, et al.
Publicado: (1998)

Identification of Cyclophilin B‐derived Peptides Capable of Inducing Histocompatibility Leukocyte Antigen‐A2‐restricted and Tumor‐specific Cytotoxic T Lymphocytes
por: Tamura, Mayumi, et al.
Publicado: (2001)

Early phase II study of mixed 19‐peptide vaccine monotherapy for refractory triple‐negative breast cancer
por: Toh, Uhi, et al.
Publicado: (2020)

Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine
por: Koga, Noriko, et al.
Publicado: (2017)

PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer
por: Waki, Kayoko, et al.
Publicado: (2014)

Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer
por: Takayama, Koichi, et al.
Publicado: (2016)

Immune responses of patients without cancer recurrence after a cancer vaccine over a long term
por: Suekane, Shigetaka, et al.
Publicado: (2022)

Dissection and identification of regions required to form pseudoparticles by the interaction between the nucleocapsid (N) and membrane (M) proteins of SARS coronavirus
por: Hatakeyama, Seisuke, et al.
Publicado: (2008)

Prognostic Factors for Overall Survival in Patients with HCV-Related HCC Undergoing Molecular Targeted Therapies: Beyond a Sustained Virological Response
por: Minami, Yasunori, et al.
Publicado: (2022)

Identification of parathyroid hormone-related protein-derived peptides immunogenic in human histocompatibility leukocyte antigen-A24(+) prostate cancer patients
por: Yao, A, et al.
Publicado: (2004)

Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients
por: Suefuji, Y, et al.
Publicado: (2001)

EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation
por: Yamada, Teppei, et al.
Publicado: (2013)

Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer
por: Waki, Kayoko, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2fol0sicos340u7js1ugjq5lt4